Spyre Therapeutics Stock Investor Sentiment

SYRE Stock   18.40  0.49  2.74%   
About 54% of Spyre Therapeutics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Spyre Therapeutics suggests that some traders are interested. The current market sentiment, together with Spyre Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Spyre Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Spyre Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Spyre Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a day ago at news.google.com         
Wolfe Research Initiates Spyre Therapeutics at Outperform With 27 Price Target -March 18, 2025 at 07...
Google News at Macroaxis
over a week ago at news.google.com         
Spyre Therapeutics Announces Grants of Inducement Awards - cnhinews.com
Google News at Macroaxis
over a week ago at gurufocus.com         
Spyre Therapeutics Inc Announces Stock Option Grants to Non-Executive Employees
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Circ, Circulose, REUP, Syre unite for textile recyclingpolicy change
Yahoo News
over a week ago at eu-startups.com         
Denmarks next big players 10 Promising startups you should keep an eye on in 2025
news
over two weeks ago at news.google.com         
Spyre Therapeutics Targeting The Future Of IBD Treatment - Seeking Alpha
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Spyre Therapeutics Announces Earnings Results, Beats Estimates By 0.08 EPS
news
over two weeks ago at thelincolnianonline.com         
Spyre Therapeutics Releases Quarterly Earnings Results, Beats Expectations By 0.08 EPS
news
over two weeks ago at gurufocus.com         
Decoding Spyre Therapeutics Inc A Strategic SWOT Insight
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Spyre Therapeutics Q4 Earnings Snapshot
Yahoo News
over two weeks ago at seekingalpha.com         
Spyre Therapeutics GAAP EPS of -0.81 beats by 0.21
seekingalpha News
over two weeks ago at gurufocus.com         
Spyre Therapeutics Inc Announces Positive Developments and Financial Results for 2024
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Spyre Therapeutics Inc Announces Participation in March Investor Conferences
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
Spyre Therapeutics Announces Promising Preclinical Results at ECCO Congress
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohns and Col...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Spyre Therapeutics that are available to investors today. That information is available publicly through Spyre media outlets and privately through word of mouth or via Spyre internal channels. However, regardless of the origin, that massive amount of Spyre data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Spyre Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Spyre Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Spyre Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Spyre Therapeutics alpha.

Spyre Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by King-jones Heidy of 95500 shares of Spyre Therapeutics at 21.66 subject to Rule 16b-3
01/15/2025
2
Spyre Therapeutics Outperform Rating Reiterated at Wedbush
01/16/2025
3
Spyre Therapeutics, Inc. Given Consensus Rating of Buy by Analysts - MarketBeat
01/23/2025
4
Spyre Unveils Strategic Talent Retention Plan 35K Options with 10-Year Window - StockTitan
02/07/2025
5
Spyre Therapeutics announces 180M private placement - TipRanks
02/11/2025
6
Spyre Therapeutics initiated with early-stage designation at Goldman Sachs - TipRanks
02/18/2025
7
Spyre Therapeutics Inc Announces Participation in March Investor Conferences
02/25/2025
8
Spyre Therapeutics GAAP EPS of -0.81 beats by 0.21
02/27/2025
9
Circ, Circulose, REUP, Syre unite for textile recyclingpolicy change
03/06/2025
10
Wolfe Research Initiates Spyre Therapeutics at Outperform With 27 Price Target -March 18, 2025 at 0717 am EDT - Marketscreener.com
03/18/2025

Complementary Tools for Spyre Stock analysis

When running Spyre Therapeutics' price analysis, check to measure Spyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spyre Therapeutics is operating at the current time. Most of Spyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Spyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spyre Therapeutics' price. Additionally, you may evaluate how the addition of Spyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios